Navigation Links
Blood-thinning copycat enters malaria fight
Date:6/1/2010

New treatments for malaria are possible after Walter and Eliza Hall Institute scientists found that molecules similar to the blood-thinning drug heparin can stop malaria from infecting red blood cells.

Malaria is an infection of red blood cells that is transmitted by mosquitoes. The most common form of malaria is caused by the parasite Plasmodium falciparum which burrows into red blood cells where it rapidly multiplies, leading to massive numbers of parasites in the blood stream that can cause severe disease and death.

At the moment, all anti-malarials licensed for use in humans block the development of the parasite within the red blood cell.

But Dr James Beeson, Ms Michelle Boyle and Dr Jack Richards from the institute's Infection and Immunity division, along with colleagues at the Burnet Institute and Imperial College London, have identified a new approach that could stop the parasite infecting red blood cells in the first place.

Using real-time video microscopy of red blood cell infection, the team showed that heparin-like carbohydrates blocked the ability of the malaria parasite to infect cells, Dr Beeson said.

"The malaria parasite needs a protein called MSP1 if it is to infect red blood cells as MSP1 is involved in the initial attachment of the parasite to the cells," Dr Beeson said.

"We have shown that heparin-like carbohydrates bind to MSP1 which stops the parasite from properly attaching to the red blood cell and, therefore, from invading."

The findings are published today in the international journal Blood and have raised the prospect of developing new anti-malarials that are based on the structure and activity of heparin-like molecules.

Although humans produce heparin-like molecules naturally, they do not occur at high enough levels in the blood to have anti-malarial activity, Dr Beeson said. "Heparin itself wouldn't be suitable as an anti-malarial as it prevents
'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-417-125-700
Walter and Eliza Hall Institute
Source:Eurekalert  

Page: 1 2

Related biology news :

1. New blood-thinning drug safer than rat poison
2. NHGRI funds new Centers for Excellence in Ethical, Legal and Social Implications Research
3. DFG to establish 10 new collaborative research centers
4. US and UK research centers launch major collaboration on atmospheric research, technology
5. AMBER Alert Safety Centers to Provide Child Safety Precautions at the New Jersey State Fair at the Meadowlands
6. Weight Watchers vs. fitness centers
7. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
8. NSF and EPA establish 2 centers for environmental implications of nanotechnology
9. Sicilian word enters British genetic language
10. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers
11. Tellme Enters Automotive Market
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood-thinning copycat enters malaria fight
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... OXFORD, Conn. , Jan. 26, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... a new corporate website ( http://www.nxt-id.com/ ) as part ... Wocket™ smart wallet. The Company launched its new consumer ... Gino Pereira , CEO of NXT-ID said, "Our ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... in cells that may help to kill tumors with heat. ... by a combination of heat and an anti-cancer drug that ... ability of heat to switch off essential survival mechanisms in ... underlying principles are still unclear. In a recent publication ...
... with large, lace-like wings that live in a wide variety ... but the larvae are ferocious predators of other insects, frequently ... after killing them using their enormous, sucking tube-like jaws. ... in the genus Semachrysa is described from the ...
... that the extremely hot, dry and windy conditions on Black ... rolls, -similar to streamers of wind flowing through the air ... the first of its kind to produce such detailed, high-resolution ... for future fire management and warning systems. The work ...
Cached Biology News:Unusual weather events identified during the Black Saturday bushfires 2
(Date:3/3/2015)... -- Thingee Corporation, a software development company for the Life ... Adoption: Making Reps, Lives Easier" during the 2015 Synergistix ...  in Deerfield Beach, Florida , taking ... to learn how technology can help them do their ... audience for the Thingee presentation. ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Genedata, ... drug discovery and life science research, today announced ... (TM) enterprise platform for use at Pfizer biopharma ... Europe. Genedata is supporting Pfizer’s global deployment and ... (GBT), Centers for Therapeutic Innovation (CTI), and Pharmaceutical ...
(Date:3/3/2015)... FRANCISCO , March 3, 2015  Johnson & ... @ South San Francisco (JLABS @SSF), ... Boulevard, South San Francisco, Calif. ... accommodate up to 50 startups from across the healthcare ... health.  The first resident startups have ...
(Date:3/3/2015)... Nev. , March 3, 2015  PDL BioPharma, ... ) today announced that the third of three shareholder ... dismissed without prejudice. On February 2, 2015, ... last September on behalf of a putative class of ... Inc., et al., No. 2:14-CV-01526-APG-NJK (D. Nev.), was voluntarily ...
Breaking Biology Technology:Thingee to present at 11th Annual Synergistix Users Conference 2Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5PDL BioPharma Announces Dismissal of Third and Final Shareholder Lawsuit 2
... Stallergenes,S.A. officially inaugurates its new pharmaceutical production ... comply with the most stringent EMEA (European Medicines,Agency) ... this unit will,produce desensitisation treatments for all markets, ... worth more than 20 million euros will incorporate ...
... Sept. 10 Signalife, Inc. (Amex:,SGN) announced that the company,s ... stock to be effected in the form of a,reverse stock ... on September,19, 2008, which will be the record date and ... time of such reverse stock split, all,outstanding shares of Signalife ...
... - Abstracts 185 and 1112, Sanofi-aventis, ... from,two randomized clinical studies presented at the European ... Meeting demonstrating that the,"basal plus" insulin strategy with ... insulin) and APIDRA(R) once daily,(prandial insulin) (insulin glulisine ...
Cached Biology Technology:Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World 2Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 2Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 3Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 4Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 5Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment 6Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 2Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 3Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes 4
Antibodies were affinity purified using epitopes specific to Alpha4 immobilized on solid support....
Prepared in distilled water....
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Biology Products: